▸ 6 Oct 2026, 10:15 Investor Presentation - Transforming Cancer Detection Presentations
▸ 1 Oct 2026, 18:23 Change in substantial holding Substantial Holders
▸ 30 Sep 2026, 08:48 BREASTESTplus 2 clinically validated Company Update
▸ 23 Sep 2026, 10:43 BCAL Introduces Avantect Multi-Cancer Early Detection Test Company Update
▸ 18 Sep 2026, 08:22 Letter to Shareholders re Annual General Meeting Meetings & Governance
▸ 18 Sep 2026, 08:22 Notice of Annual General Meeting/Proxy Form Meetings & Governance
▸ 10 Sep 2026, 13:19 Clarification of BCAL's Position in Relation to GSS Other
▸ 3 Sep 2026, 12:40 BCAL Seeks Board Change at Genetic Signatures Company Administration
▸ 3 Sep 2026, 11:47 Investor Presentation September 2026 Presentations
▸ 31 Aug 2026, 14:30 Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM Presentations
▸ 28 Aug 2026, 15:46 Appendix 4G and Corporate Governance Statement Company Administration
▸ 28 Aug 2026, 15:44 Appendix 4E and Annual Report to shareholders Financial Results
▸ 26 Aug 2026, 08:57 BCAL Takes Interest in Genetic Signatures to 18.46% Substantial Holders
▸ 26 Aug 2026, 08:35 Change in Substantial Shareholder Notice for GSS Other
▸ 25 Aug 2026, 18:53 Notification regarding unquoted securities - BDX Securities Administration
▸ 21 Aug 2026, 18:27 Notification regarding unquoted securities - BDX Securities Administration
▸ 21 Aug 2026, 18:18 Proposed issue of securities - BDX Securities Administration
▸ 21 Aug 2026, 18:14 BCAL Secures Funding for FY2027 Update Periodic Reports
▸ 6 Aug 2026, 09:34 Bioshares Conference Investor Presentation Presentations
▸ 30 Jul 2026, 08:38 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Reports
▸ 14 Jul 2026, 18:51 Notification regarding unquoted securities - BDX Securities Administration
▸ 14 Jul 2026, 18:44 Notification regarding unquoted securities - BDX Securities Administration
▸ 14 Jul 2026, 18:32 Notification regarding unquoted securities - BDX Securities Administration
▸ 14 Jul 2026, 18:20 Notification regarding unquoted securities - BDX Securities Administration
▸ 2 Jul 2026, 17:13 Becoming a substantial holder for GSS Other
▸ 2 Jul 2026, 10:04 BCAL to Acquire Shares in Genetic Signatures Company Update
▸ 29 Jun 2026, 09:57 BCAL Secures Funding for FY2027 Periodic Reports
▸ 18 Jun 2026, 09:52 BCAL Develops New Blood Test for Breast Cancer Recurrence Company Update
▸ 28 May 2026, 08:25 Validation Agreement Signed with Sonic USA, for Breastest V2 Company Update
▸ 19 May 2026, 10:09 BCAL Launches Early Detection Cancer Platform Company Update
▸ 11 May 2026, 08:23 BCAL Appoints Anne-Louise Arnett as Chief Executive Officer Company Administration
▸ 22 Apr 2026, 08:50 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Reports
▸ 31 Mar 2026, 09:11 BCAL Submits MSAC Application for Avantect Pancreatic Test Company Update
▸ 26 Mar 2026, 09:19 BCAL Accelerates Rollout of Avantect Early Detection Tests Company Update
▸ 20 Mar 2026, 17:08 Change of Director's Interest Notice Director Interests
▸ 19 Mar 2026, 17:21 Change of Director's Interest Notice Director Interests
▸ 17 Mar 2026, 15:31 Change of Director's Interest Notice Director Interests
▸ 6 Mar 2026, 15:21 Cleansing Notice Securities Administration
▸ 6 Mar 2026, 15:14 Application for quotation of securities - BDX Securities Administration
▸ 20 Feb 2026, 19:26 Change of Director's Interest Notice Director Interests
▸ 18 Feb 2026, 11:33 BCAL Half Year Results Presentation December 2025 Financial Results
▸ 17 Feb 2026, 19:47 Half Yearly Report and Accounts Financial Results
▸ 13 Feb 2026, 10:13 BCAL Webinar Review Half Year Results 18 February 11am AEDT Presentations
▸ 5 Feb 2026, 08:24 Shareholder Update Company Update
▸ 3 Feb 2026, 08:45 Initial Director's Interest Notice Director Interests
▸ 27 Jan 2026, 08:51 Mr Mark McConnell Appointed to the Board Company Administration
▸ 21 Jan 2026, 08:53 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Reports
▸ 19 Jan 2026, 15:23 Change in substantial holding Substantial Holders
▸ 15 Dec 2025, 08:19 Application for quotation of securities - BDX Securities Administration
▸ 9 Dec 2025, 08:23 Pancreatic and Ovarian Cancer Early Detection Blood Testing Company Update
▸ 3 Dec 2025, 08:28 Ethics Approval to Establish BREASTEST Registry Company Update
▸ 28 Nov 2025, 13:17 Results of Meeting Meetings & Governance
▸ 28 Nov 2025, 10:47 BCAL AGM Presentation Presentations
▸ 26 Nov 2025, 08:29 BCAL Receives R&D Tax Offset $2.5 million Periodic Reports
▸ 19 Nov 2025, 08:32 BCAL Early Cancer Detection Tests Update Company Update
▸ 7 Nov 2025, 08:28 Change of Director's Interest Notice Director Interests
▸ 31 Oct 2025, 09:08 Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Reports
▸ 28 Oct 2025, 16:38 Letter to Shareholders Re Annual General Meeting Meetings & Governance
▸ 28 Oct 2025, 16:38 Notice of Annual General Meeting/Proxy Form Meetings & Governance
▸ 27 Oct 2025, 18:35 Application for quotation of securities - BDX Securities Administration
▸ 21 Oct 2025, 09:40 Proposed issue of securities - BDX Securities Administration
▸ 20 Oct 2025, 09:50 BCAL Establishes $10m Convertible Note Facility Revised Securities Administration
▸ 20 Oct 2025, 08:28 BCAL Establishes $10 million Convertible Note Facility Securities Administration
▸ 24 Sep 2025, 09:27 Investor Update Presentations
▸ 23 Sep 2025, 10:48 Investor Webinar 24 September 2025 11am AEST Presentations
▸ 18 Sep 2025, 10:00 BCAL and ClearNote Partner on Early Cancer Detection Tests Company Update
▸ 8 Sep 2025, 08:24 Change of Director's Interest Notice Director Interests
▸ 8 Sep 2025, 08:24 Final Directors Interest Notice X 2 Director Interests
▸ 29 Aug 2025, 15:25 Appendix 4G Corporate Governance Statement Company Administration
▸ 29 Aug 2025, 09:44 Appendix 4E and Annual Report Financial Results
▸ 29 Aug 2025, 08:43 Retirement of Non-Executive Directors Company Administration
▸ 27 Aug 2025, 09:10 BCAL Partners with Sonic Healthcare Company Update